A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

Exclusion Criteria

• •History of or current neurological/psychiatric, respiratory, cardiovascular, gastrointestinal, hematological and lymphatic, endocrine, or musculoskeletal system diseases, hepatic or renal insufficiency, or any other disease or physiological condition that may affect the study results;
• •Subjects with a personal or family history of medullary thyroid cancer (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2);
• •History of chronic pancreatitis or an episode of acute pancreatitis within 3 months prior to screening;
• •History of a cholecystitis episode within 3 months prior to screening;
• •History of allergy to HDM1002, moxifloxacin hydrochloride tablets, other fluoroquinolones or quinolones, or any of the excipients; or history of food allergy, or a specific allergy history (asthma, urticaria, eczema, etc.);
• •Clinically significant major illness or undergone major surgery within 3 months prior to the trial;
• •Blood donation within 3 months, or plans to donate blood during this study, or transfusion or blood loss ≥200 mL within 4 weeks prior to the trial;
• •Has consumed a special diet, engaged in strenuous exercise, or had other factors that affect drug absorption, distribution, metabolism, and excretion within 48 hours prior to dosing;
• •Pregnant or lactating, or has a positive blood pregnancy test result;
• •The investigator believes that the subject has any other condition that makes them unsuitable for participation in this clinical trial.